Cellectric is developing a direct-from-blood application for sepsis samples, selectively destroying human cells in the patient sample with the aim to bypass the need for culturing of the bacteria. The technology focuses on isolating target bacteria within minutes to accelerate the sepsis diagnosis workflow, with the goal of enabling faster, more effective sepsis patient management.
“We are excited to join forces with Gradientech, whose ultra-rapid AST platform is already setting new standards in clinical microbiology,” says Terje Wimberger, Managing Director at Cellectric. “Together, we will explore how the technology of Cellectric can resolve sample complexity and improve overall workflow efficiency, ultimately contributing to faster, more accurate treatment decisions for sepsis patients worldwide.”
“Cellectric’s cutting-edge approach to rapidly isolating bacteria directly from whole blood is true innovation. When combined with the ultra-rapid QuickMIC system, we can together not just improve workflows—we can redefine what’s possible in sepsis diagnostics and set a new benchmark for innovation in the clinical diagnostics market,” says Sara Thorslund, co-founder and CEO at Gradientech.
QuickMIC® and its gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.
